IGF-1 LR3 vs Follistatin 344

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), giving it a longer half-life and higher receptor availability than native IGF-1. Preclinical research has examined its effects on PI3K/Akt/mTOR signaling, muscle protein synthesis, and cellular proliferation models. Follistatin 344 is the 344-amino-acid isoform of follistatin, a glycoprotein that binds and neutralizes members of the TGF-beta superfamily — most notably myostatin and activin. By antagonizing myostatin (a negative regulator of muscle growth), Follistatin 344 has been studied in muscle hypertrophy and tissue regeneration models. It works upstream of the growth pathway rather than directly stimulating receptors.

IGF-1 LR3

Mechanism Direct IGF-1 receptor activation
Pathway PI3K/Akt/mTOR signaling
IGFBP Binding Minimal (resistant to IGFBPs)
Research Focus Muscle protein synthesis, proliferation
Half-Life ~20-30 hours (extended)
Biological Class Growth factor analog

Follistatin 344

Mechanism Myostatin/activin antagonism
Pathway TGF-beta superfamily inhibition
IGFBP Binding Not applicable
Research Focus Muscle hypertrophy, fibrosis research
Half-Life Extended (binds and neutralizes ligands)
Biological Class TGF-beta family antagonist

The Verdict

IGF-1 LR3 and Follistatin 344 both appear in muscle and growth research but operate through opposite directions in the signaling pathway. IGF-1 LR3 directly activates growth signaling at the receptor level, while Follistatin 344 removes a negative regulator (myostatin) to allow endogenous growth signaling to proceed. They are mechanistically complementary — some research protocols use both to study upstream and downstream effects on the same biological outcome.

IGF-1 LR3 vs Follistatin 344 — FAQ

Why is IGF-1 LR3 modified instead of using native IGF-1?
The arginine substitution and N-terminal extension reduce binding to IGF-binding proteins, which would otherwise sequester native IGF-1 and limit its receptor availability in research models.
How does Follistatin work without binding to a receptor?
Follistatin acts as a ligand trap — it binds directly to myostatin and other TGF-beta family members, preventing them from reaching their receptors. This removes negative growth regulation rather than adding positive signaling.
Can they be combined?
Yes. Their non-overlapping mechanisms (direct receptor activation vs antagonist removal) make them complementary in preclinical muscle research.
What is the regulatory status?
Both are sold as research-use-only compounds for in-vitro and preclinical study models.

References

Primary sources for key clinical and regulatory claims on this page.

  1. IGF-I receptor signalling and the regulation of skeletal muscle mass — PubMed / Int J Biochem Cell Biol . Comprehensive review of IGF-1 receptor signaling and the PI3K/Akt/mTOR pathway in muscle research.
  2. Follistatin antagonizes activin signaling and acts with notch to regulate muscle growth — PubMed / Mol Cell Biol . Primary preclinical reference for follistatin antagonism of TGF-beta family signaling in muscle models.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides Category
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now